Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Inks Deal with MultiPlan to Include MaterniT21 Plus Test

NEW YORK (GenomeWeb News) – Sequenom today announced an expanded agreement with healthcare cost management firm MultiPlan to include the MaterniT21 Plus LDT test for fetal aneuploidies.

As a result of the deal, MultiPlan's network of 900,000 providers will have access to Sequenom's test for trisomy 21, 18, and 13. The test was launched in October.

One of Sequenom's goals for 2012 is to sign two major national insurers as well as smaller payors in order to drive up adoption of the test. Earlier this week, the company increased its estimates for the number of billed MaterniT21 tests to 40,000 in 2012, up from a previous forecast of 25,000.

The Scan

Rare Genetic Disease Partnership

A public-private partnership plans to speed the development of gene therapies for rare genetic diseases, Stat News writes.

Approval Sought for Alzheimer's Drug

The Wall Street Journal reports Eli Lilly has initiated a rolling submission to the US Food and Drug Administration to seek approval for its drug to treat Alzheimer's disease.

DNA Barcoding Paper Retracted

Science reports that a 2014 DNA barcoding paper was retracted after a co-author brought up data validity concerns.

Nature Papers Present Genomic Analysis of Bronze Age Mummies, Approach to Study Host-Pathogen Interactions

In Nature this week: analysis finds Tarim mummies had local genetic origin, and more.